Alzheimer’s disease (AD) is a chronic progressive neurodegenerative disorder. In recent years, early diagnosis technologies represented by imaging and humoral biomarkers resulted in continued evolution of the AD diagnostic criteria and laid the foundation for the research and development of disease modification therapy. The advancement of fluid and imaging biomarkers resulted in continued evolution of the criteria and facilitated the development of disease modifying therapy. This, however, pertained clearly shortcomings, particularly when applied in a clinical setting. In 2021, DUBOIS and the International Working Group presented the current limitations of pure biomarkers in the diagnosis of AD and proposed recommendations for whether to detect biomarkers in clinical practice. This paper reviews the evolution of AD diagnostic criteria and provides insights for the clinical and research applications accordingly.